[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 60 of about 60
1. Brito NM, Brito MV, Carvalho Rde K, Matos LT, Lobato RC, Correa SC, Brito RB: The effect of copaiba balsam on Walker 256 carcinoma inoculated into the vagina and uterine cervix of female rats. Acta Cir Bras; 2010 Apr;25(2):176-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of copaiba balsam on Walker 256 carcinoma inoculated into the vagina and uterine cervix of female rats.
  • PURPOSE: To verify the copaiba balsam (Copaifera officinalis) effect on Walker 256 carcinoma inoculated into vagina and uterine cervix of rats.
  • On the 1st day of the experiment, 0.3 ml of Walker 256 carcinoma (2x10(6) concentration) was inoculated in both groups; on the 3rd day of the experiment, it was given 4.8 ml/kg of distilled water to the GC group, and 4.8 ml/kg of copaiba balsam to the GCop group.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305885.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Balsams; 0 / copaiba balsam
  •  go-up   go-down


2. Alves AP, Pessoa Cdo O, Costa-Lotufo L, Moraes Filho MO: Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma. Acta Cir Bras; 2007 Nov-Dec;22(6):457-64
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma.
  • PURPOSE: To investigate the effects of bisphosphosnate alendronate (ALD) and metotrexate (MTX) on an experimental model of Walker 256 carcinosarcoma developed in the oral cavity of rats.
  • METHODS Walker 256 carcinosarcoma cell suspension (0,1 mL) containing 10(6) cell/mL was implanted in the alveoli of the first and second molars.
  • CONCLUSION: The bisphosphonate alendronate exherted an osteoprotective effect and induced bone neoformation on the Walker 256 carcinosarcoma inoculated in rat mandibles.
  • The combination of metotrexate with bisphosphonate alendronate is more successful than treatment with the agents alone in controlling the growth of neoplastic cells and in stimulating reactive new bone.
  • Therefore, this may be an alternative treatment to malignant lesions of maxillaries with osteolysis.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235934.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; X1J18R4W8P / Alendronate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X: Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol; 2003 Nov;9(11):2445-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study.
  • In this study, we examined the effect of TACE on angiogenesis and expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) and to assess their relevance to Walker-256 transplanted hepatoma.
  • METHODS: Male Wistar rats were inoculated with Walker-256 tumor in the left lobe of liver.
  • Sixty rats bearing walker-256 transplanted hepatoma were randomly divided into control group, arterial infusion group and TACE group.
  • MVD of the control group, chemotherapy group and chemoemoblization group was 80.84+/-24.24, 83.05+/-20.29 and 85.20+/-23.91 (F=0.193, P=0.873), respectively.
  • CONCLUSION: There has been little influence of lipiodol chemoembolization on the formation of tumor angiogenesis, but the development of neovascularization and expression of VEGF play important roles in establishment of collateral circulation and reconstruction of blood supply of residual cancer tissue.
  • [MeSH-major] Carcinoma 256, Walker / physiopathology. Chemoembolization, Therapeutic. Fibroblast Growth Factor 2 / metabolism. Liver Neoplasms, Experimental / physiopathology. Neovascularization, Pathologic / therapy. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14606073.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC4656518
  •  go-up   go-down


Advertisement
4. Sasajima T, Shimada N, Naitoh Y, Takahashi M, Hu Y, Satoh T, Mizoi K: (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int J Cancer; 2007 Dec 15;121(12):2637-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
  • Malignant tumor cells (RG2 and C6 gliomas, Walker 256 carcinoma) were incubated with low dose vincristine (VCR) to induce multidrug resistance.
  • MTT assay demonstrated a significant increase of surviving fractions in VCR-resistant sublines compared to those of drug-naive cells.
  • Reverse transcriptase polymerase chain reaction revealed higher expression of MDR1 mRNA in VCR-resistant cells than drug-naive cells in each line.
  • Volume distribution (V(d)) of (99m)Tc-MIBI was negatively correlated with MDR1 mRNA expression among drug-naive and VCR-resistant cells.
  • Autoradiographic images of (99m)Tc-MIBI revealed higher uptake in drug-naive cells at basal ganglia compared with VCR-resistant cells at the opposite basal ganglia of rats.
  • Therapeutic effects of VCR with or without the MDR1 inhibitors were also evaluated autoradiographically using (14)C-methyl-L-methionine ((14)C-Met) and MIB-5 index. (14)C-Met uptake and MIB-5 index of both tumors treated with VCR following the MDR1 inhibitor treatment significantly decreased compared with tumors treated with VCR alone.
  • Analysis of (99m)Tc-MIBI accumulation is considered informative for detecting MDR1-mediated drug resistance and for monitoring the therapeutic effects of MDR1 inhibitors in malignant brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / radionuclide imaging. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / radionuclide imaging. P-Glycoprotein / antagonists & inhibitors. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Animals. Autoradiography. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclosporine / pharmacology. Cyclosporins / pharmacology. Cytotoxins / pharmacology. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Drug Synergism. Predictive Value of Tests. Quinolines / pharmacology. RNA, Messenger / metabolism. Radiopharmaceuticals. Rats. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17708555.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / Cytotoxins; 0 / P-Glycoprotein; 0 / Quinolines; 0 / RNA, Messenger; 0 / Radiopharmaceuticals; 0BJK6B565B / dofequidar; 121584-18-7 / valspodar; 5J49Q6B70F / Vincristine; 83HN0GTJ6D / Cyclosporine; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


5. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J: Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv; 2009 Jul;6(3):255-60
Hazardous Substances Data Bank. Sulfur, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Success of selective drug therapies depends on the drug's depot time in the target to treat.
  • Depot time is currently being prolonged, using drug-eluting beads or microspheres for selective internal radiation therapy.
  • The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size.
  • MATERIALS AND METHODS: An animal model with two different vascularized tumors (Walker Carcinoma 256 (hypervascularized) and Yoshida Sarcoma (hypovascularized)) was used.
  • Tumor activity was measured with a gamma camera at 10 min, 1h, 3h, 6h, 14h and 48h p.i.
  • Measurements were adjusted for decay times and then compared.
  • CONCLUSIONS: Particle stay time, biodistribution, and stability can be easily monitored as shown in this animal model.
  • Prolonged retention is independent of vascularization and particle size and appears to be sufficient for therapy.
  • [MeSH-minor] Animals. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / metabolism. Epinephrine / pharmacology. Female. Humans. Injections, Intralesional. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Radioisotopes / chemistry. Rats. Rats, Wistar. Rhenium / chemistry. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / metabolism. Serum Albumin / chemistry. Spleen / metabolism. Sulfur / chemistry. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604139.001).
  • [ISSN] 1567-2018
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0 / rhenium sulfur colloid; 70FD1KFU70 / Sulfur; 7440-15-5 / Rhenium; YKH834O4BH / Epinephrine
  •  go-up   go-down


6. Wu HP, Feng GS, Tian Y: Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats. World J Gastroenterol; 2005 Apr 28;11(16):2408-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the distribution and stability of antisense oligodeoxynucleotide (ASODN) in Walker-256 cells and their distribution in liver, lung and kidney tissues after being infused alone or mixed with lipiodol via hepatic artery in a rat liver tumor model.
  • METHODS: 5'-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media.
  • Its distribution in cells was observed by fluorescence microscope at different time points.
  • Walker-256 carcinosarcoma was transplanted into Wistar rat liver to establish a liver cancer model.
  • Frozen samples of liver, lung and kidney tissue were taken from rats after 1, 3 and 6 d, respectively.
  • In mixed group, ASODN was mainly distributed in liver tumor tissues.
  • CONCLUSION: ASODN can transfect Walker-256 cells.
  • ASODN mixed with lipiodol infusion via hepatic artery can be used in the treatment of HCC.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Contrast Media / pharmacokinetics. Iodized Oil / pharmacokinetics. Liver Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Fluorescein-5-isothiocyanate / pharmacokinetics. Fluorescent Dyes / pharmacokinetics. Hepatic Artery. Male. Neoplasm Transplantation. Rats. Rats, Wistar. Specific Pathogen-Free Organisms. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832409.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 8001-40-9 / Iodized Oil; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC4305626
  •  go-up   go-down


7. Levi M, DeRemer SJ, Dou C, Ensminger WD, Smith DE: Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. Biopharm Drug Dispos; 2004 Jan;25(1):27-35
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Amifostine is a prodrug in which selectivity is largely determined by the preferential formation and uptake of its cytoprotective metabolite, WR-1065, in normal tissues as a result of differences in membrane-bound alkaline phosphatase activity.
  • It was hypothesized that amifostine may be a good candidate for regional drug delivery to the liver because of its large hepatic extraction and total body clearance.
  • METHODS: Rat livers were implanted with Walker-256 tumors.
  • WR-1065 concentrations in the blood, liver and tumor were measured at various times.
  • CONCLUSIONS: Amifostine may provide increased liver protection and decreased tumor protection from radio- or chemotherapy when administered by the portal vein.
  • [MeSH-major] Amifostine / administration & dosage. Amifostine / metabolism. Drug Delivery Systems / methods. Liver Neoplasms, Experimental / drug therapy. Mercaptoethylamines / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / surgery. Disease Models, Animal. Drug Screening Assays, Antitumor. Femoral Vein / drug effects. Infusions, Intravenous. Male. Neoplasm Transplantation / methods. Portal Vein / drug effects. Prodrugs / administration & dosage. Prodrugs / metabolism. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 John Wiley & Sons, Ltd.
  • (PMID = 14716750.001).
  • [ISSN] 0142-2782
  • [Journal-full-title] Biopharmaceutics & drug disposition
  • [ISO-abbreviation] Biopharm Drug Dispos
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098502
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mercaptoethylamines; 0 / Prodrugs; 31098-42-7 / WR 1065; M487QF2F4V / Amifostine
  •  go-up   go-down


8. Kurth AH, Kim SZ, Sedlmeyer I, Hovy L, Bauss F: Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br; 2000 Jan;82(1):126-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with ibandronate preserves bone in experimental tumour-induced bone loss.
  • The third-generation bisphosphonate, ibandronate (BM 21.0955), is a potent compound for controlling tumour osteolysis and hypercalcaemia in rats bearing Walker 256 carcinosarcoma.
  • We have studied the effect of ibandronate given as an interventional treatment on bone strength and bone loss after the onset of tumour growth in bone.
  • Our results suggest that it is capable of preserving bone quality in rats bearing Walker 256 carcinosarcoma cells.
  • Since other bisphosphonates have produced comparable results in man after their success in the Walker 256 animal models our findings suggest that ibandronate may be a powerful treatment for maintaining skeletal integrity in patients with metastatic bone disease.
  • [MeSH-major] Bone Resorption / drug therapy. Carcinoma 256, Walker / complications. Diphosphonates / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10697328.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


9. Ovsjanko EV, Lushnikova EL, Larionov PM, Arkhipov SA, Nepomnyashchikh LM, Efremov AV, Ovsjanko YU: Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs. Bull Exp Biol Med; 2009 Oct;148(4):650-5
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs.
  • Immunohistochemical study was performed to evaluate the expression of Bcl-2 family proteins (Bcl-2, Bax, and Bad) in Walker 256 carcinosarcoma cells after implantation into the thigh muscle of male Wistar rats (10(6) cells).
  • The experiment was conducted under conditions of spontaneous tumor development and individual or combined treatment with melatonin and cyclophosphamide.
  • The use of melatonin as monotherapy or in combination with cyclophosphamide was followed by a significant decrease in Bcl-2 expression in carcinosarcoma cells.
  • The Bcl-2/Bax and Bcl-2/Bad ratio was significantly reduced under these conditions (particularly after combined treatment with cytostatic drugs).
  • Daily treatment with melatonin was accompanied by significant changes in the structure of Walker 256 carcinosarcoma.
  • It was manifested in the formation of connective tissue septa and pseudofollicles.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Cytostatic Agents / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Antioxidants / therapeutic use. Cyclophosphamide / therapeutic use. Humans. Male. Melatonin / therapeutic use. Neoplasm Transplantation. Rats. Rats, Wistar. Tumor Cells, Cultured. bcl-2-Associated X Protein / metabolism. bcl-Associated Death Protein / metabolism

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396763.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antioxidants; 0 / Cytostatic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0 / bcl-Associated Death Protein; 8N3DW7272P / Cyclophosphamide; JL5DK93RCL / Melatonin
  •  go-up   go-down


10. Novaes MR, Lima LA, Ribeiro JE, Magalhães AV, Sousa MV, Morhy L: [Pharmacological effects of arginine supplementation in rats with Walker 256 solid tumor]. Arch Latinoam Nutr; 2000 Sep;50(3):230-6
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacological effects of arginine supplementation in rats with Walker 256 solid tumor].
  • [Transliterated title] Efeitos farmacológicos da suplementação dietética com arginina em ratos com tumor sólido de Walker 256.
  • We evaluate the effects of dietetic supplementation with arginine over body weight, growth of tumor, metastatic dissemination, surviving time, amino acid metabolism, haematological changes of the rats with Walker 256 solid tumor.
  • The supplementation with arginine was associated with a lower weight gain during the study period (p < 0.05).
  • Surviving time of the rats with solid tumor did not vary significantly between the groups.
  • The rate of metastase was lower in animals with Walker 256 solid tumor supplemented with arginine.
  • Anaemia was less severe in the rats with Walker 256 solid tumor that received arginine supplementation.
  • The results suggest that arginine 6% supplementation may have pharmacologic effect in rats with Walker 256 solid beyond the nutritional one.
  • [MeSH-major] Arginine / therapeutic use. Carcinoma 256, Walker / drug therapy. Dietary Supplements
  • [MeSH-minor] Amino Acids / blood. Analysis of Variance. Animals. Body Weight. Case-Control Studies. Disease-Free Survival. Drug Screening Assays, Antitumor. Male. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11347291.001).
  • [ISSN] 0004-0622
  • [Journal-full-title] Archivos latinoamericanos de nutrición
  • [ISO-abbreviation] Arch Latinoam Nutr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Amino Acids; 94ZLA3W45F / Arginine
  •  go-up   go-down


11. Plotnikov MB, Maslov MIu, Aliev OI, Vasil'ev AS, Zueva EP, Krylova SG, Shilova NV: [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats]. Vopr Onkol; 2001;47(3):335-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats].
  • [Transliterated title] Narusheniia reologicheskikh svoĭstv krovi u krys s kartsinosarkomoĭ 256 Walker i pri khimioterapii tsiklofosfanom.
  • Tumor process development in rats inoculated with cellular suspension of transplantable Walker's carcinosarcoma-256 involved enhanced thickening of blood on day 7.
  • Treatment with 20 mg/kg cyclophosphamide, thrice a day, every other day, retarded tumor process and brought hemorheologic indices further down, at the same time.
  • Similar treatment of intact rats with cyclophosphamide caused hemorheologic disorders too.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Cyclophosphamide / pharmacology. Hemorheology / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11544834.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Kolganov AS: [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia]. Vopr Onkol; 2001;47(1):81-5
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia].
  • [Transliterated title] Eksperimental'naia khimioterapiia zlokachestvennykh opukholeĭ v sochetanii s kratkovremennoĭ obshcheĭ gipoksieĭ.
  • The effect of hypoxy on chemotherapy with emoxyl, 5-fluorouracil and bleomycin which are characterized by different affinities with oxygen has been investigated.
  • In an experiment using 96 rats, each weighing 180 g, subcutaneously inoculated with Walker's carcinosarcoma and carcinoma.
  • PC-1, combined use of chemotherapy and hypoxy was followed by a significant inhibition of tumor growth rate, against a background of significant drop in survival due to the increased toxic effect of the drugs.
  • Therefore, hypoxy cannot be recommended for modifying chemotherapy of tumors irrespective of drug affinity with oxygen.
  • [MeSH-major] Anoxia. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carcinoma 256, Walker / therapy. Daunorubicin / analogs & derivatives. Daunorubicin / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317544.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 84412-94-2 / Emoxyl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


13. Dima VF, Ionescu MD: Ultrastructural changes induced in Walker carcinosarcoma by treatment with dihematoporphyrin ester and light in animals with diabetes mellitus. Roum Arch Microbiol Immunol; 2000 Jan-Jun;59(1-2):119-30
Hazardous Substances Data Bank. ALLOXAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrastructural changes induced in Walker carcinosarcoma by treatment with dihematoporphyrin ester and light in animals with diabetes mellitus.
  • The purpose of this study was to evaluate by electron microscopy the tumoral fine structure changes induced by photodynamic therapy (PDT) in diabetic animals.
  • Walker -256 carcinosarcoma harvested from animals with/without diabetes mellitus exposed to PDT (Photofrin II/5 mg/kg and 24 hrs later He-Ne laser irradiation/632.8 nm; 10 mW) and examined by electron microscopy showed different degrees of lesions in the nucleus and cytoplasmic fine structure.
  • The ultrastructural changes induced by PDT in animals with diabetes mellitus bearing carcinosarcoma are characterized by: lysis of chromatin situated on the central zone of nucleus; swelling and vacuolization of mitochondria; formation of phagosome--like structures; myelin figures; degenerescence and disappearance of cytoplasmic organelles.
  • Summing up, the data presented in this work demonstrate that the exposure to three doses of PDT produces changes in tumoral fine structure, increases survival rate and reduces incidence of carcinosarcoma in rats with diabetes mellitus.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Diabetes Mellitus, Experimental / complications. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11845470.001).
  • [ISSN] 1222-3891
  • [Journal-full-title] Roumanian archives of microbiology and immunology
  • [ISO-abbreviation] Roum Arch Microbiol Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6SW5YHA5NG / Alloxan; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


14. Qin XJ, He W, Hai CX, Liang X, Liu R: Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol; 2008 Apr;28(3):271-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy.
  • Although antioxidant treatment is a promising method to prevent the side effects, protection by a single antioxidant is limited.
  • A rat tumor model with a transplanted tumor in the liver was treated with adriamycin and ANTIOXIN was used as a protection.
  • The results showed that adriamycin chemotherapy increased the level of malondialdehyde (MDA), nitrogen oxide (NO) and decreased the activities of total superoxide dismutase (T-SOD), manganese superoxide dismutase (MnSOD), catalase (CAT), glutathione (GSH) and total antioxidant capacity (TAC).
  • Adriamycin chemotherapy also decreased the expression of Bcl-2, increased the expression of iNOS and cell apoptosis in the liver and kidney.
  • These data demonstrated that adriamycin chemotherapy could cause oxidative stress to the whole body, on which multiple antioxidants based on the theory of 'multiple antioxidant chain' had effective protection.
  • [MeSH-major] Antibiotics, Antineoplastic / toxicity. Antioxidants / therapeutic use. Carcinoma 256, Walker / drug therapy. Doxorubicin / toxicity. Liver Neoplasms / drug therapy
  • [MeSH-minor] Animals. Catalase / metabolism. Drug Therapy, Combination. Drugs, Chinese Herbal. Glutathione / metabolism. Kidney / drug effects. Kidney / metabolism. Lipid Peroxidation / drug effects. Liver / drug effects. Liver / metabolism. Longevity / drug effects. Malondialdehyde / metabolism. Medicine, Chinese Traditional. Nitric Oxide Synthase Type II / metabolism. Nitrogen Dioxide / metabolism. Oxidative Stress / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley. Superoxide Dismutase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582587.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antioxidants; 0 / Drugs, Chinese Herbal; 0 / Proto-Oncogene Proteins c-bcl-2; 4Y8F71G49Q / Malondialdehyde; 80168379AG / Doxorubicin; EC 1.11.1.6 / Catalase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, rat; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


15. Novaes MR, Lima LA, Novaes LC, Souza MV: Metabolic and hematological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor. Ann Nutr Metab; 2004 Nov-Dec;48(6):404-8
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic and hematological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor.
  • The aim of the present study is to evaluate the effects of dietary supplementation with arginine on metastatic dissemination, amino acid metabolism, hematological functions of rats with Walker 256 ascitic tumor.
  • The findings suggest that arginine supplementation at 6% may have a beneficial effect on to the host, besides its pharmacological action.
  • [MeSH-major] Amino Acids / metabolism. Arginine / metabolism. Arginine / therapeutic use. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Dietary Supplements. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Male. Neoplasm Metastasis / drug therapy. Random Allocation. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15583469.001).
  • [ISSN] 0250-6807
  • [Journal-full-title] Annals of nutrition & metabolism
  • [ISO-abbreviation] Ann. Nutr. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Amino Acids; 94ZLA3W45F / Arginine
  •  go-up   go-down


16. Jumes FM, Lugarini D, Pereira AL, de Oliveira A, Christoff Ade O, Linde GA, do Valle JS, Colauto NB, Acco A: Effects of Agaricus brasiliensis mushroom in Walker-256 tumor-bearing rats. Can J Physiol Pharmacol; 2010 Jan;88(1):21-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Agaricus brasiliensis mushroom in Walker-256 tumor-bearing rats.
  • This work aimed to investigate the antitumoral activity of A. brasiliensis extracts and pure powdered basidiocarp preparation using Walker-256 (W256) tumor-bearing rats, a model for cancer-related cachexia studies.
  • The results showed that all 4 treatments (pure powdered basidiocarp and aqueous, acid, and alkaline extracts) significantly reduced tumor size and promoted gain in body weight.
  • The data collected from the W256 tumor-bearing rats revealed the beneficial effects of A. brasiliensis in tumor treatment, mainly related to cachexia.
  • [MeSH-major] Agaricus. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma 256, Walker / drug therapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Male. Oxidative Stress / drug effects. Oxidative Stress / physiology. Phytotherapy / methods. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130735.001).
  • [ISSN] 1205-7541
  • [Journal-full-title] Canadian journal of physiology and pharmacology
  • [ISO-abbreviation] Can. J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


17. Taveira VC, Novaes MR, Dos Anjos Reis M, da Silva MF: Hematologic and metabolic effects of dietary supplementation with Agaricus sylvaticus fungi on rats bearing solid walker 256 tumor. Exp Biol Med (Maywood); 2008 Nov;233(11):1341-7
MedlinePlus Health Information. consumer health - Dietary Supplements.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic and metabolic effects of dietary supplementation with Agaricus sylvaticus fungi on rats bearing solid walker 256 tumor.
  • BACKGROUND: Many mushrooms have been used since ancient times for their nutritional and therapeutic properties.
  • OBJECTIVE: The aim of the present study was to evaluate the effects of Agaricus sylvaticus on hematologic and biochemical parameters of rats inoculated with Walker 256 tumor.
  • Group 1 was inoculated with Walker 256 tumor and treated with A. sylvaticus.
  • Group 2 was inoculated with Walker 256 tumor and administered a placebo solution.
  • Group 3 was not inoculated with the tumor and was treated with A. sylvaticus, and Group 4 was not inoculated with the tumor and was administered a placebo solution.
  • The rats were sacrificed after 12 days of treatment, and blood was collected following heart sectioning.
  • [MeSH-major] Agaricus. Anemia / drug therapy. Carcinoma 256, Walker / complications. Dietary Supplements / adverse effects

  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703747.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Zalietok SP, Orlovs'kyĭ OA, Hohol' SV, Samoĭlenko OA, Hulua L, Kvesitadze HI: [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats]. Lik Sprava; 2006 Dec;(8):89-93
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats].
  • Green tea biocomposite had effectivey hampered the growth of rat Walker W-256 carcinoma and in less extent rat Guerin's carcinoma.
  • Black tea biocomposite had not practically influenced on Guerin's carcinoma growth.
  • The biocomposite from green tea and extract from red vine rind and lemon suppressed at the level of tendency the growth of rat Walker W-256 carcinoma.
  • The biocomposite from green tea and extract from red vine rind had hampered only Guerin's carcinoma growth and at the tendency had increased the growth of W-256 carcinosarcoma growth.
  • This biocomposite increased also considerably the therapeutic efficiency of cisplatin on Guerin's carcinoma.

  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427433.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador A, Pinto GJ, Jakobi S, Gobbo-Bordon D, Rohn TV, Fabrício VE, Moretto KD, Tosta E, Curi R, Fernandes LC: Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett; 2003 Nov 25;201(2):139-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats.
  • We examine the potential benefits of combination of different anabolic agents such as insulin and clenbuterol associated to prostaglandin synthesis inhibitor (naproxen) on tumor growth, cachexia and renal function in Walker 256 tumor-bearing rats (WK).
  • Treatment begins at the 4th day after tumor inoculation, at the 14th day they were killed, glycemia, lacticidemia, glycogen content from liver, soleus and gastrocnemius muscles, tumor mass, body weight and kidney function were determined.
  • Tumor weight was significantly reduced by the different treatments.
  • Naproxen treatment (WK N) induced an increased by 14%.
  • [MeSH-major] Cachexia / drug therapy. Carcinoma 256, Walker / drug therapy. Clenbuterol / therapeutic use. Insulin / therapeutic use. Naproxen / therapeutic use
  • [MeSH-minor] Adrenergic beta-Agonists / therapeutic use. Animals. Blood Glucose / analysis. Body Weight / drug effects. Cyclooxygenase Inhibitors / therapeutic use. Drug Therapy, Combination. Eating / drug effects. Energy Intake. Glycogen / metabolism. Kidney / drug effects. Kidney / pathology. Liver / drug effects. Liver / pathology. Muscle, Skeletal / drug effects. Muscle, Skeletal / pathology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NAPROXEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14607327.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Blood Glucose; 0 / Cyclooxygenase Inhibitors; 0 / Insulin; 57Y76R9ATQ / Naproxen; 9005-79-2 / Glycogen; XTZ6AXU7KN / Clenbuterol
  •  go-up   go-down


20. Mund RC, Pizato N, Bonatto S, Nunes EA, Vicenzi T, Tanhoffer R, de Oliveira HH, Curi R, Calder PC, Fernandes LC: Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation. Prostaglandins Leukot Essent Fatty Acids; 2007 Feb;76(2):113-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation.
  • Then, they were inoculated with a suspension of Walker 256 ascitic tumor cells (2 x 10(7)ml) and after 14 days they were killed.
  • Supplementation with FO resulted in significantly lower tumor weight, greater tumor cell apoptosis, lower ex vivo tumor cell proliferation, a higher tumor content of lipid peroxides, lower expression of cyclooxygenase-2 (COX-2) in tumor tissue and a lower plasma concentration of prostaglandin E2 than observed in rats fed regular chow or supplemented with coconut oil.
  • These results suggest that reduction of tumor growth by FO involves an increase in apoptosis and of lipid peroxidation in tumor tissue, with a reduction in tumor cell proliferation ex vivo, COX-2 expression and PGE2 production.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma 256, Walker / diet therapy. Cyclooxygenase 2 / drug effects. Dinoprostone / blood. Fish Oils / pharmacology. Lipid Peroxidation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234396.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fish Oils; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


21. Pizato N, Bonatto S, Yamazaki RK, Aikawa J, Nogata C, Mund RC, Nunes EA, Piconcelli M, Naliwaiko K, Curi R, Calder PC, Fernandes LC: Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats. Nutr Cancer; 2005;53(2):194-201
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats.
  • In this study we investigate the impact of the dietary ratio of n-6 to n-3 fatty acids (FAs) from postweaning until adult age upon tumor growth, lipid peroxidation in tumor tissue, and metabolic indicators of cancer cachexia in Walker 256 tumor-bearing rats.
  • After 8 wk, half of each group was inoculated with 1 ml of 2 x 10(7) Walker 256 cells.
  • [MeSH-major] Body Weight / drug effects. Cachexia / diet therapy. Carcinoma 256, Walker / metabolism. Fatty Acids, Omega-3 / pharmacology. Fatty Acids, Omega-6 / pharmacology. Fatty Acids, Unsaturated / pharmacology
  • [MeSH-minor] Animals. Cholesterol / blood. Dose-Response Relationship, Drug. Energy Intake. Fish Oils. Male. Plant Oils. Random Allocation. Rats. Rats, Wistar. Time Factors. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Body Weight.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573380.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Fatty Acids, Unsaturated; 0 / Fish Oils; 0 / Plant Oils; 0 / Triglycerides; 8001-21-6 / sunflower seed oil; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


22. Su M, Qiu Y, Jia W: A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats. Adv Ther; 2005 Jul-Aug;22(4):297-306
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibitory effects of gallium ethylenediamine-N,N,N',N'-tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Chelating Agents / therapeutic use. Gallium / therapeutic use. Organophosphorus Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418139.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chelating Agents; 0 / Organophosphorus Compounds; 1429-50-1 / (ethylenedinitrilo)-tetramethylenephosphonic acid; CH46OC8YV4 / Gallium
  •  go-up   go-down


23. Nunes EA, Kuczera D, Brito GA, Bonatto SJ, Yamazaki RK, Tanhoffer RA, Mund RC, Kryczyk M, Fernandes LC: Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression. Nutr Res; 2008 Jul;28(7):487-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression.
  • Cancer cachexia syndrome contributes to wasting and weight loss leading to inefficacy of anticancer therapy.
  • In this study, the anticatabolic agent beta-hydroxy-beta-methylbutyrate (HMB) was supplemented to adult Walker 256 tumor-bearing rats during 8 weeks aiming to determine if tumor burden could be reduced.
  • In conclusion, HMB supplementation, at a similar dose used in humans to increase muscle mass, caused antitumor and anticachectic effects, with tumor-cell nuclear factor-kappaB pathway participation, which might be a potential nutritional strategy in cancer therapy.
  • [MeSH-major] Cachexia / prevention & control. Carcinoma 256, Walker / pathology. NF-kappa B / analysis. Valerates / administration & dosage
  • [MeSH-minor] Animals. Cell Division / drug effects. Glycogen / analysis. Liver / chemistry. Male. Muscle, Skeletal / chemistry. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19083450.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Valerates; 3F752311CD / beta-hydroxyisovaleric acid; 9005-79-2 / Glycogen
  •  go-up   go-down


24. Calin MA, Gruia MI, Herascu N, Coman T: Photodynamic therapy of Walker tumors by multiple laser irradiation. Photomed Laser Surg; 2005 Aug;23(4):405-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of Walker tumors by multiple laser irradiation.
  • OBJECTIVE: Photodynamic therapy of Walker tumor after subcutaneous administration of 5-ALA solution using a multiple laser irradiation scheme was monitored by the fluorescence imaging technique to investigate the effectiveness of 5-ALA-PDT.
  • BACKGROUND DATA: Photodynamic therapy (PDT) is a localized cancer treatment based on the selective uptake and retention of photosensitizer at the tumoral level and on the activation of the photosensitizer by a specific wavelength of light, aiming to induce cytotoxic reactions.
  • As a new photosensitizer, the heme precursor 5- aminolevulinic acid has been introduced recently for photodynamic therapy of tumors and precancerous lesions of the skin.
  • CONCLUSIONS: In conclusion, the use of a multiple laser irradiation scheme, for the activation of reaccumulation of Pp IX (with three steps) is effective for photodynamic therapy of Walker tumor.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Carcinoma 256, Walker / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Protoporphyrins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144485.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


25. Togni V, Ota CC, Folador A, Júnior OT, Aikawa J, Yamazaki RK, Freitas FA, Longo R, Martins EF, Calder PC, Curi R, Fernandes LC: Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation. Nutr Cancer; 2003;46(1):52-8
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation.
  • Then they were inoculated subcutaneously with Walker 256 tumor cells.
  • Furthermore, FO supplementation partly abolished the fall in serum glucose, totally prevented the elevation in serum lactate concentrations, partly prevented the hypertriacylgylcerolemia, and preserved tissue glycogen stores.
  • [MeSH-major] Cachexia / drug therapy. Carcinoma 256, Walker / drug therapy. Dietary Supplements. Fatty Acids, Unsaturated / therapeutic use. Hypolipidemic Agents / therapeutic use. Triglycerides / therapeutic use
  • [MeSH-minor] Analysis of Variance. Animals. Blood Glucose / drug effects. Body Weight / drug effects. Fatty Acids, Omega-3. Female. Glycogen / metabolism. Lactic Acid / blood. Lipid Metabolism. Male. Pregnancy. Prenatal Exposure Delayed Effects. Rats. Rats, Wistar. Survival Rate

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12925304.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Unsaturated; 0 / Hypolipidemic Agents; 0 / Triglycerides; 100085-40-3 / Pikasol; 33X04XA5AT / Lactic Acid; 9005-79-2 / Glycogen
  •  go-up   go-down


26. Tandon VK, Yadav DB, Chaturvedi AK, Shukla PK: Synthesis of (1,4)-naphthoquinono-[3,2-c]-1H-pyrazoles and their (1,4)-naphthohydroquinone derivatives as antifungal, antibacterial, and anticancer agents. Bioorg Med Chem Lett; 2005 Jul 1;15(13):3288-91
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structure-activity relationship of these compounds was studied and the results show that the compound 2b exhibited in vitro antifungal activity against Candida albicans and Cryptococcus neoformans, and also possessed antibacterial profile against Klebsiella pneumoniae and Escherichia coli whereas 1c showed anticancer activity against Walker 256 Carcinosarcoma in rats.
  • [MeSH-minor] Animals. Candida albicans / drug effects. Carcinoma 256, Walker / drug therapy. Cryptococcus neoformans / drug effects. Escherichia coli / drug effects. Klebsiella pneumoniae / drug effects. Microbial Sensitivity Tests. Naphthoquinones / pharmacology. Rats. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913995.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Pyrazoles
  •  go-up   go-down


27. Calin MA, Gruia Ml, Herascu N, Coman T: The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid. J Exp Ther Oncol; 2004 Oct;4(3):247-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid.
  • Photodynamic therapy with protoporphyrin IX induced by delta-aminolevulinic acid (ALA) is mainly applied for the treatment of human superficial skin cancer.
  • In this paper we present our study on photodynamic therapy (PDT) of the implanted Walker tumours using subcutaneous administration of ALA to improve the availability of ALA in the skin.
  • The temporal behavior of PpIX fluorescence has shown a clear demarcation of tumoural zone depending on the post-administration time and the administrated concentration of the ALA solution.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Photochemotherapy. Photosensitizing Agents / pharmacokinetics. Protoporphyrins / pharmacokinetics
  • [MeSH-minor] Animals. Injections, Subcutaneous. Rats. Rats, Wistar. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724844.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


28. Knox RJ, Burke PJ, Chen S, Kerr DJ: CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des; 2003;9(26):2091-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CB 1954: from the Walker tumor to NQO2 and VDEPT.
  • Unfortunately, for the treatment of human disease, this anti-tumor selectivity was seen only in certain rat tumors.
  • The bioactivation of CB 1954 in rat cells involves the aerobic reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NQO1 (DT-diaphorase).
  • A gene therapy-based approach for targeting cancer cells and making them sensitive to CB 1954 and related compounds has been developed.
  • VDEPT (gene-directed enzyme prodrug therapy) has been used to express an E. coli nitroreductase in tumor cells and human tumor cells transduced to express this enzyme are very sensitive to prodrugs activated by nitroreduction.
  • When active, NQO2 is 3000 times more effective than human DT-diaphorase in the reduction of CB 1954.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Aziridines / pharmacology. Carcinoma 256, Walker / enzymology. Genetic Therapy / methods. Prodrugs / pharmacology. Quinone Reductases / metabolism
  • [MeSH-minor] Animals. Cell Survival / drug effects. Escherichia coli / enzymology. Humans. Nitroreductases / genetics. Nitroreductases / metabolism. Rats. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529407.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aziridines; 0 / Prodrugs; 7865D5D01M / tretazicar; EC 1.6.99.- / NRH - quinone oxidoreductase2; EC 1.6.99.- / Quinone Reductases; EC 1.7.- / Nitroreductases
  • [Number-of-references] 98
  •  go-up   go-down


29. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical trial of the antitumoral therapeutic effectiveness of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):105-18
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical trial of the antitumoral therapeutic effectiveness of some natural polyphenolic biopreparations.
  • We studied the therapeutic effect of different doses on the tumor generation process and compared it with the experimental oncostatic action of several standard chemotherapeutic drugs of clinical use (thiotepa, methotrexate, melphalan and cyclophosphamide).
  • In our experimental treatment with the bioactive polyphenolic agents, we have used various doses, both higher and lower than the dose that had conditioned the expression of their antitumoral action upon Guerin T-8 lymphotropic epithelioma and upon Walker 256 carcinosarcoma.
  • We compared the evaluation indices of the antitumoral pharmacodynamic effect we obtained in the treatment with the POLYAS biopreparations with those of reference cytostatic agents.
  • Antitumoral effectiveness can be improved by an experimental manipulation of the therapeutic doses--which proves the existence of a dose-response relationship.
  • The quantitative preclinical evaluation of the specific pharmacodynamic effect will be complemented by the investigation of the new polyphenolic biopreparations therapeutic effectiveness in tumors with various degrees of development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413151.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


30. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical qualitative evaluation of the antitumoral pharmacodynamic action of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):91-103
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of in vivo tests of their effect on the development of Guerin T-8 lymphotropic epithelioma and Walker 256 carcinosarcoma were conducted.
  • All those results highlighted the antineoplastic pharmacotherapeutic effect of the polyphenolic biopreparations and also proved that effect to be replicable.
  • The qualitative evaluation of the pharmacodynamic action of those preparations was a condition for their further quantitative pharmacological evaluation in point of antitumoral therapeutic effectiveness in a preclinical stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413150.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


31. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
  • [Transliterated title] Citotoxicidad de la beta-lapachona: una o-naftoquinona con posibles usos terapéuticos.
  • Initial observations proved its capability for inhibiting growth of Yoshida tumor and Walker 256 carcinosarcoma. beta-Lap redox-cycling in the presence of reductants and oxygen yields "reactive oxygen species" (ROS: O2-, OH and H2O2) which cytotoxicity led to assume its role in beta-lap activity in cells. beta-Lap inhibited DNA synthesis in Trypanosoma cruzi as well as topoisomerases I and II, poly(ADP-ribose) polymerase (PARP) in different cells.
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


32. Clichici S, Filip A, Daicoviciu D, Ion RM, Mocan T, Tatomir C, Rogojan L, Olteanu D, Muresan A: The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung; 2010 Mar;97(1):41-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin.
  • Photodynamic therapy (PDT) is a promising therapy especially in skin cancer, using the systemic administration of a photosensitizer (PS), followed by the local irradiation of the tumor with visible light.
  • Our study evaluates the effects of PDT with TSPP upon the tumor levels of ROS and upon the metalloproteinases 2 (MMP2) activities on Wistar male rats bearing 256 Walker carcinosarcoma in correlation with the accumulation of PS in the tumor and with the intratumor histological alterations.
  • Our results emphasize that 24 hours after the PDT with TSPP, the ROS generation increases, as revealed by protein carbonyls and malondialdehyde levels and the antioxidant capacity (hydrogen donors, thiol groups) decreases in the tumor tissue.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Photochemotherapy. Porphyrins / therapeutic use. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Animals. Antioxidants / metabolism. Kinetics. Male. Matrix Metalloproteinase 2 / metabolism. Oxidative Stress / drug effects. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use. Rats. Rats, Wistar. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233689.001).
  • [ISSN] 0231-424X
  • [Journal-full-title] Acta physiologica Hungarica
  • [ISO-abbreviation] Acta Physiol Hung
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Reactive Oxygen Species; 35218-75-8 / tetraphenylporphine sulfonate; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


33. Mihalache D, Preoteasa V, Barca V: Effects of combined selenium and vitamin E administration on DNA in Walker tumor bearing Wistar rat exposed to cytostatic acute treatment. Roum Arch Microbiol Immunol; 2003 Jul-Dec;62(3-4):239-50
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of combined selenium and vitamin E administration on DNA in Walker tumor bearing Wistar rat exposed to cytostatic acute treatment.
  • Previous studies have showed that organic Se and Vitamin E have a significant protective effect when administered in combination with cytostatics.
  • This paper reports the investigation on effects of mixed administration Orgasel 50 and Vitamin E in Wistar rat with experimentally induced Walker tumor under acute cytostatic treatment, with emphasis on two aspects: a) the influence of antioxidants upon liver unscheduled DNA biosynthesis under cytostatic (Lomustin) acute aggression; and b) the potential improvement of cytostatic effects by antioxidants treatment in tumor.
  • The Walker tumor (an epithelial carcinoma) cells were subcutaneously injected (5 x 10(6) cells/0.5 ml in isotonic saline solution); the first tumor nodules appeared in 4 days; the tumor has reached the appropriate dimensions in 12 days.
  • The unscheduled DNA biosynthesis caused by Lomustin in rat liver as well as the replicative DNA biosynthesis taking place in Walker tumor cells were assessed radioisotopically by measuring the uptake of 3H-Thymidine (200 microCi / 100 g.b.w.).
  • Our observations regarding the role of antioxidant treatment suggest:.
  • The most significant results were showed in both analyzed tissues, when the Orgasel 50 + Vitamin E administration begins at the same time with the tumor cell inoculation.
  • These findings clearly show the organic Se salts and Vitamin E constitute a valuable adjuvant in anticancer medication, increasing the interest for the application of these antioxidants in cancer therapy and prevention.
  • [MeSH-major] Antioxidants / therapeutic use. Carcinoma 256, Walker / drug therapy. Selenium / therapeutic use. Selenium Compounds / therapeutic use. Vitamin E / therapeutic use. Yeast, Dried / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Drug Combinations. Drug Therapy, Combination. Injections, Intramuscular. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELENIUM DISULFIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008147.001).
  • [ISSN] 1222-3891
  • [Journal-full-title] Roumanian archives of microbiology and immunology
  • [ISO-abbreviation] Roum Arch Microbiol Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Drug Combinations; 0 / Selenium Compounds; 0 / orgasel; 1406-18-4 / Vitamin E; 7488-56-4 / selenium disulfide; H6241UJ22B / Selenium
  •  go-up   go-down


34. Dowell JA, Sancho AR, Anand D, Wolf W: Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Adv Drug Deliv Rev; 2000 Mar 15;41(1):111-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors.
  • An effective methodology to determine the amount of cisplatin or carboplatin at the solid tumor site in a noninvasive manner may enable clinicians to design drug regimens based on an individual's in situ pharmacokinetics.
  • Such noninvasive methods may allow optimization of an individual's drug exposure at the target site, as well as provide a screening measure to determine individual efficacy based on exposure to these platinated drugs.
  • 195mPt appears to be the radionuclide of platinum most suitable for radiolabeling cisplatin or carboplatin, and an analysis is presented of the methods available for preparing such radiolabeled drugs.
  • The animals used were Sprague Dawley rats bearing the Walker 256 carcinoma, and drug biodistribution was studied following administration of cisplatin or carboplatin radiolabeled with 195mPt.
  • This radionuclide permitted noninvasive imaging of the drug and its metabolites at the tumor site and at selected organs.
  • The results obtained show an ability to estimate the amount of platinated drug species in the tumor environment using a noninvasive methodology.
  • This noninvasive method is able to provide individual estimates of the active component of the drug at the target site, and is therefore a method that can be implemented in human studies.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Organoplatinum Compounds / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10699308.001).
  • [ISSN] 0169-409X
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 38
  •  go-up   go-down


35. Welchinskaya HV, Piecuszak B, Kovalenko EA, Sharykina NI, Getman KI, Podgorsky VS: Biological activity of bacterial lectins and their molecular complexes with heterocyclic bis-adducts. Mikrobiol Z; 2003 Sep-Oct;65(5):20-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was discovered that these substances apply to a few toxic preparations and have a expression antitumour action on the tumours: Walker carcinosarcoma 256, Pliss' lymphosarcoma and Sarcoma 45.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Heterocyclic Compounds / chemistry. Lectins / chemistry. Lectins / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Bacillus / chemistry. Benzimidazoles / chemistry. Carcinoma 256, Walker / drug therapy. Crown Ethers. Halothane / chemistry. Imidazoles / chemistry. Lethal Dose 50. Lymphoma, Non-Hodgkin / drug therapy. Mice. Rats. Sarcoma, Experimental / drug therapy. Uracil / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE .
  • Hazardous Substances Data Bank. BENZIMIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723158.001).
  • [ISSN] 1028-0987
  • [Journal-full-title] Mikrobiolohichnyĭ zhurnal (Kiev, Ukraine : 1993)
  • [ISO-abbreviation] Mikrobiol. Z.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Crown Ethers; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Lectins; 56HH86ZVCT / Uracil; 63J177NC5B / 18-crown-6; 7GBN705NH1 / imidazole; E24GX49LD8 / benzimidazole; UQT9G45D1P / Halothane
  •  go-up   go-down


36. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • We next investigated the effect of the DXR contents of CMPul-DXR conjugates on their body distribution in rats bearing Walker 256.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


37. DiResta GR, Lee J, Healey JH, Larson SM, Arbit E: Enhancing the uptake of chemotherapeutic drugs into tumors using an "artificial lymphatic system". Ann Biomed Eng; 2000 May;28(5):556-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the uptake of chemotherapeutic drugs into tumors using an "artificial lymphatic system".
  • This paper presents findings from uptake studies to evaluate the ability of an "artificial lymphatic system" (ALS) to enhance large and small molecular weight drug transport into solid tumors and the therapeutic effect of the additional drug on their growth.
  • Walker 256, Neuroblastoma, and Sarcoma dual-tumor models were used to evaluate the effect of ALS aspiration on the uptake of 3F8 monoclonal antibody, and doxorubicin.
  • A tumor shrinkage experiment using Walker 256 dual tumors was used to evaluate the efficacy of an implantable ALS with cyclophosphamide chemotherapy.
  • Drug uptake significantly increased in all aspirated tumors; 3F8 uptake was enhanced 37.4% in the Walker and 93.1% in the Neuroblastoma tumor lines (p<0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Artificial Organs. Lymphatic System. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Biological Transport, Active. Biomedical Engineering. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Carcinoma 256, Walker / pathology. Cyclophosphamide / administration & dosage. Cyclophosphamide / pharmacokinetics. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Male. Neuroblastoma / drug therapy. Neuroblastoma / metabolism. Neuroblastoma / pathology. Rats. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / metabolism. Sarcoma, Experimental / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10925953.001).
  • [ISSN] 0090-6964
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA78494-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


38. Paterson AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer; 2000 Jun 15;88(12 Suppl):3038-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
  • Within the family of BPs there are more similarities in pharmacologic effects than differences, although side effect profiles, rates of oral absorption, and potency do differ.
  • Oral clodronate and intravenous pamidronate reduce skeletal complications in patients with bone metastases from breast carcinoma (as well as in myeloma).
  • Uncontrolled trials of prostate carcinoma also suggest clinical benefit.
  • METHODS: Animal studies show that BPs can reduce the rate of development of bone metastases (for example, in Walker 256 carcinoma), but there is little evidence of an effect at nonosseous sites.
  • RESULTS: In patients with recurrent breast carcinoma but no overt bone metastases, oral clodronate reduced the number of diagnosed bone metastases; but the number of patients who had relapses in bone, though smaller, was not significantly different from the number among patients who took placebo.
  • Patients treated for operable breast carcinoma have four or five times the normal rate of vertebral fracture, and BPs do reduce the rate of bone loss.
  • ), showed a reduction in osseous and nonosseous recurrences and an increase in disease free and overall survival with 2 years of clodronate.
  • A second open-label trial (Saarto et al.) of similar size involving lymph node positive breast carcinoma patients showed no effect on the rate of bone metastasis relapse and a deleterious effect on relapse rates of nonosseous metastases with 3 years of clodronate.
  • A third placebo-controlled trial involving 1079 patients reported, in an interim analysis, a reduction in osseous metastases during treatment with 2 years of clodronate, but no effect on nonosseous metastases or survival.
  • 1) scientifically, it is important to demonstrate that an agent that has its dominant effect on a normal tissue cell, the osteoclast, can influence the growth of neoplastic cells; and 2) from the perspective of patient care, it must be unequivocally shown that a reduction in the rate of osseous recurrence translates into an improvement in disease free survival or an improvement in quality of life through reduction of adverse skeletal events.
  • The National Surgical Adjuvant Breast Project has committed to conducting this study and including women with operable breast carcinoma.
  • [MeSH-major] Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Diphosphonates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Clinical Trials as Topic. Female. Humans. Spinal Fractures / etiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898349.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 62
  •  go-up   go-down


39. Tao K, Chen D, Tian Y, Wu Z: [The cytotoxic effects of the adriamycin magnetic albumin microspheres combined with external magnetic fields on the malignant tumor cells]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2001 Jun;18(2):223-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study sought to assess the inhibitory effects of the adriamycin magnetic albumin microspheres (ADM-MAMs) on Walker-256 malignant tumor cells in vitro induced by the permanent magnetic fields.
  • The cultured Walker-256 cells were divided into three groups; the group of ADM-MAMs combined with magnetic fields, the group of AMD-MAMs without magnetic fields, and ADM group.
  • [MeSH-major] Albumins. Carcinoma 256, Walker / pathology. Doxorubicin / pharmacology. Magnetics / therapeutic use
  • [MeSH-minor] Animals. Cell Size / drug effects. Cell Size / radiation effects. Combined Modality Therapy. Microspheres. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450539.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 80168379AG / Doxorubicin
  •  go-up   go-down


40. Yin Q, Cheng W, Cheng MY, Fan SZ, Shen W: Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav Pharmacol; 2010 Oct;21(7):595-601
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syngeneic Walker 256 mammary gland carcinoma cells were injected into the tibia medullary cavity to establish the rat model of bone cancer pain.
  • [MeSH-major] Antibodies, Neutralizing. Bone Neoplasms / complications. Carcinoma 256, Walker / complications. Pain / immunology. Pain Management. Receptors, Chemokine / immunology
  • [MeSH-minor] Animals. Disease Models, Animal. Hyperalgesia / physiopathology. Hyperalgesia / therapy. Injections, Spinal. Molecular Targeted Therapy / trends. Pain Measurement / drug effects. Pain Measurement / psychology. Pain Threshold / drug effects. Pain Threshold / psychology. Rats. Rats, Sprague-Dawley. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736819.001).
  • [ISSN] 1473-5849
  • [Journal-full-title] Behavioural pharmacology
  • [ISO-abbreviation] Behav Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neutralizing; 0 / CX3CR1 protein, rat; 0 / Receptors, Chemokine
  •  go-up   go-down


41. Stepensky D, Golomb G, Hoffman A: Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci; 2002 Feb;91(2):508-16
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two rat models of bone disease were applied.
  • Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy.
  • Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion.
  • Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration.
  • [MeSH-minor] Animals. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / urine. Bone Resorption / drug therapy. Calcium / blood. Calcium / urine. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Carcinoma 256, Walker / urine. Drug Administration Schedule. Drug Evaluation, Preclinical / methods. Female. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / urine. Male. Neoplasm Transplantation. Parathyroidectomy. Rats. Rats, Sprague-Dawley. Rats, Wistar. Thyroidectomy. Tibia / pathology

  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:508-516, 2002
  • (PMID = 11835209.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


42. Chen JH, Ling R, Yao Q, Wang L, Ma Z, Li Y, Wang Z, Xu H: Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery. World J Gastroenterol; 2004 Jul 1;10(13):1989-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Walker-256 carcinosarcomas were surgically implanted into the left liver lobes of 60 male Wistar rats, which were divided into 4 groups at random (15 rats per group).
  • Survival time, tumor enlargement ratio, and tumor necrosis degree were compared between each group.
  • The mean tumor-bearing survival time was 39.50 days.
  • CONCLUSION: Therapeutic effect of ADR on liver malignancy can be significantly enhanced by its nanopaticle formulation and administration via hepatic artery.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Carcinoma 256, Walker / drug therapy. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacology. Liver Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Hepatic Artery. Injections, Intra-Arterial. Male. Nanotechnology. Necrosis. Particle Size. Random Allocation. Rats. Rats, Wistar. Survival Analysis

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222053.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC4572247
  •  go-up   go-down


43. Kremer P, Hartung G, Bauder-Wüst U, Schrenk HH, Wunder A, Heckl S, Zillmann U, Sinn H: Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats. Anticancer Drugs; 2002 Jul;13(6):615-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antifolate aminopterin (AMPT) was developed before methotrexate (MTX), but was not clinically established or generally used due its increased toxicity compared to MTX.
  • Recently, we reported on the increased metabolism of albumin conjugates such as methotrexate-albumin (MTX-SA) in malignant tumors and the feasibility of using albumin as a carrier for drug targeting.
  • Biodistribution, tolerability and efficacy of this novel conjugate were studied in Walker-256 (W-256) carcinoma-bearing rats.
  • At the MTD/2 in W-256 carcinoma-bearing rats, AMPT-SA achieved a 100% volume reduction and an optimal volume reduction during treatment/control (T/C) of 8.3% compared to a 53% volume reduction of AMPT and a T/C of 16.5% (p=0.032).
  • These effects are attributed to the albumin carrier which seems to be an effective tool for selective tumor drug targeting.
  • [MeSH-major] Aminopterin / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma 256, Walker / drug therapy. Folic Acid Antagonists / therapeutic use
  • [MeSH-minor] Animals. Chelating Agents. Drug Delivery Systems. Female. Neoplasm Transplantation. Pentetic Acid. Rats. Rats, Sprague-Dawley. Serum Albumin / chemistry. Tissue Distribution. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. AMINOPTERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172507.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chelating Agents; 0 / Folic Acid Antagonists; 0 / Serum Albumin; 7A314HQM0I / Pentetic Acid; JYB41CTM2Q / Aminopterin
  •  go-up   go-down


44. Sugahara S, Okuno S, Yano T, Hamana H, Inoue K: Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol Pharm Bull; 2001 May;24(5):535-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting.
  • Using the Walker 256 model for carcinosarcoma-bearing rats, we intravenously administered 5 polysaccharide carriers with various molecular weights (MWs) and electric charges and tested for their plasma and tissue distribution.
  • As for the anionic charge, CMDex (110-180 kDa) with a degree of substitution (DS) of the CM groups ranging from 0.2 to 0.6, showed maximum plasma AUC values.
  • Doxorubicin (DXR) was bound to these carriers via a peptide spacer, GlyGlyPheGly (GGFG), to give carrier-GGFG-DXR conjugates (DXR content: 4.2-7.0 (w/w)%), and the antitumor effects of these conjugates were tested with Walker 256 carcinosarcoma-bearing rats by monitoring the tumor weights after a single intravenous injection.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers. Polysaccharides / pharmacokinetics
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Doxorubicin / administration & dosage. Female. Molecular Weight. Rats. Rats, Wistar. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379776.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Polysaccharides; 80168379AG / Doxorubicin
  •  go-up   go-down


45. Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, Kuroi K, Matsumoto G, Toi M, Nakashima E: Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology; 2009;77(3-4):182-91
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC.
  • METHODS: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME).
  • RESULTS: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC(50) values for TR-BME were higher than those for TR-BBB or Walker 256.
  • Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC(50).
  • In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Endothelial Cells / drug effects. Paclitaxel / pharmacology. Stem Cells / drug effects. Taxoids / pharmacology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Cell Line. Cell Migration Inhibition / drug effects. Cell Proliferation / drug effects. Female. Humans. Neovascularization, Pathologic / drug therapy. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19729975.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


46. Xia R, Chen X: Effects of Danshen injection on the malignant obstructive jaundice in the SD rat model. J Huazhong Univ Sci Technolog Med Sci; 2006;26(6):686-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To observe the effects of Danshen on the growth of hepatocellular carcinoma in the SD rats, a model of malignant obstructive jaundice was established by inoculation of transplanted tumor into the hepatic portal with the walker-256 hepatocarcinoma line, which resulted in the obstruction by the infiltration and metastasis of hepatocellular carcinoma.
  • The liver function, morphological changes and the expressions of PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were observed after the treatment with the 4 agents.
  • The rates of carcinoma-inhibition and metastasis inhibition were significantly higher than those of NS and inosine+vitamin C (P<0.01).
  • The expressions of PCNA,VEGF and ICAM-1 PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were lower than those in control group and InV group, with the differences being significant (P<0.01).
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Jaundice, Obstructive / drug therapy. Phenanthrolines / therapeutic use
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / complications. Disease Models, Animal. Intercellular Adhesion Molecule-1 / metabolism. Liver / pathology. Liver Neoplasms / complications. Male. Neoplasm Metastasis. Proliferating Cell Nuclear Antigen / metabolism. Rats. Rats, Wistar. Vascular Endothelial Growth Factor A / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2003 Dec;22(12):1363-6 [14693071.001]
  • (PMID = 17357489.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Phenanthrolines; 0 / Proliferating Cell Nuclear Antigen; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, rat; 126547-89-5 / Intercellular Adhesion Molecule-1; 79483-68-4 / dan-shen root extract
  •  go-up   go-down


47. Tandon VK, Singh RV, Rai S, Chhor RB, Khan ZK: Synthesis and pharmacological studies of some 2-t-amino and 2,3-di-t-amino substituted 1,4-naphthoquinones and related compounds. Boll Chim Farm; 2002 Jul-Aug;141(4):304-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and pharmacological studies of some 2-t-amino and 2,3-di-t-amino substituted 1,4-naphthoquinones and related compounds.
  • [MeSH-minor] Animals. Anti-Bacterial Agents. Antifungal Agents / chemical synthesis. Antifungal Agents / pharmacology. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Antiviral Agents / chemical synthesis. Antiviral Agents / pharmacology. Bacteria / drug effects. Carcinoma 256, Walker / drug therapy. Drug Screening Assays, Antitumor. Fungi / drug effects. Indicators and Reagents. Microbial Sensitivity Tests. Viral Plaque Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12426819.001).
  • [ISSN] 0006-6648
  • [Journal-full-title] Bollettino chimico farmaceutico
  • [ISO-abbreviation] Boll Chim Farm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Indicators and Reagents; 0 / Naphthoquinones
  •  go-up   go-down


48. Cao F, Gao F, Xu AJ, Chen ZJ, Chen SS, Yang H, Yu HH, Mei W, Liu XJ, Xiao XP, Yang SB, Tian XB, Wang XR, Tian YK: Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain. Brain Res; 2010 Apr 22;1326:162-73
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain.
  • Although opioids remain the principal axis in drug therapies for CIBP, their sustained application is known to induce cellular and molecular adaptations including enhanced neuroimmune reactivity.
  • This is generally characterized by glial activation and proinflammatory cytokine production which frequently results in pharmacological tolerance.
  • This research was performed to investigate spinal neuroimmune responses after prolonged systemic morphine treatment in a rat model of CIBP.
  • The model was established using a unilateral intra-tibia injection of Walker 256 mammary gland carcinoma cells.
  • Spinal glial activation was detected by immunohistochemistry and real-time PCR; the production of proinflammatory cytokines (IL-1beta and TNF-alpha) was examined through real-time PCR and ELISA.
  • Moreover, the treatment had no significant influence on the activated spinal glia morphology, cell density and expression of special cytomembrane markers, whereas it significantly down-regulated the local proinflammatory cytokine production at the mRNA and protein level.
  • Collectively, these data suggest that chronic morphine treatment in CIBP is not concomitant with pharmacological tolerance, at least partially because the treatment fails to amplify spinal neuroimmune responses.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Gene Expression Regulation / drug effects. Interleukin-1beta / metabolism. Morphine / therapeutic use. Pain / drug therapy. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Antigens, CD11b / genetics. Antigens, CD11b / metabolism. Bone Neoplasms / complications. Carcinoma / pathology. Cell Line, Tumor. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay / methods. Female. Glial Fibrillary Acidic Protein / metabolism. Hyperalgesia / drug therapy. Hyperalgesia / etiology. Mammary Neoplasms, Experimental. Neoplasm Transplantation. Neuroglia / drug effects. Neuroglia / metabolism. Pain Threshold / drug effects. Rats. Rats, Wistar. Spinal Cord / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20176002.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antigens, CD11b; 0 / Glial Fibrillary Acidic Protein; 0 / Interleukin-1beta; 0 / Tumor Necrosis Factor-alpha; 76I7G6D29C / Morphine
  •  go-up   go-down


49. Kurth AA, Kim SZ, Shea M, Bauss F, Hayes WC, Müller R: Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. J Bone Miner Metab; 2007;25(2):86-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
  • Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only.
  • At endpoint, excised femurs were scanned using microcomputed tomography (microCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone.
  • Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. microCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group.
  • After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone and Bones / pathology. Carcinoma 256, Walker / pathology. Diphosphonates / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Femur / drug effects. Femur / pathology. Image Processing, Computer-Assisted. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 May 15;99(10 ):2509-17 [9153295.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17 (7):1139-47 [12096826.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5452-7 [8221685.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):685-93 [6428894.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Phys Med Biol. 1994 Jan;39(1):145-64 [7651993.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2324-33 [8641182.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] J Bone Miner Res. 1994 Feb;9(2):221-30 [8140935.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Anat Rec. 1997 Dec;249(4):458-68 [9415453.001]
  • [Cites] Osteoporos Int. 2001;12 (11):936-41 [11804020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):126-30 [10697328.001]
  • [Cites] Bone. 2004 Apr;34(4):736-46 [15050906.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3080-8 [10898355.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Bone. 2002 Jan;30(1):300-6 [11792601.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):1932-41 [14606504.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Osteoporos Int. 1998;8(2):97-103 [9666930.001]
  • [Cites] Calcif Tissue Int. 1996 Jan;58(1):24-9 [8825235.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):91-8 [8508433.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] Mol Pharmacol. 1996 Nov;50(5):1127-38 [8913344.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1482-91 [8889848.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Osteoporos Int. 2002 Oct;13(10):816-23 [12378371.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1167-74 [10404017.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3007-11 [6233002.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):539-43 [3119600.001]
  • [Cites] J Orthop Res. 2001 Mar;19(2):200-5 [11347691.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):35-41 [3949849.001]
  • [Cites] Drugs. 2000 Mar;59(3):391-9 [10776826.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] Oncology. 1988;45(1):41-6 [3340393.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1787-96 [15476578.001]
  • (PMID = 17323177.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; UMD7G2653W / ibandronic acid
  •  go-up   go-down


50. Gong LS, Zhang YD, Liu S: Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int; 2004 Aug;3(3):365-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to verify the effect of magnetic field application on target distribution of nanoparticles in transplanted rat liver cancer model and to find out a new method for the treatment of malignant liver tumor.
  • In the experimental group (12 rats), the tumor tissue was exposed to the magnetic field for 30 minutes.
  • Tissues of tumor, nontargeted sites of the liver, heart, kidney, lung, spleen, stomach and small intestine were analyzed for gamma-counts and examined histologically.
  • RESULTS: In the experimental group, the radioactivity of tumor tissue was 8.7 times that of liver tissue.
  • In the control group, the radioactivity of tumor tissue was 2.8 times that of normal liver tissue.
  • CONCLUSIONS: In the presence of magnetic field, magnetic albumin nanoparticles may accumulate in tumor tissues, of which the radioactivity can increase to 8.7 times that of normal liver.
  • Even if the magnetic field is not applied, magnetic albumin nanoparticles in tumor tissues still increase to 2.8 times that of normal liver tissues.
  • These findings indicate that normal organs in the presence of magnetic field are less exposed to chemotherapeutic drugs.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacokinetics. Liver Neoplasms / drug therapy
  • [MeSH-minor] Albumins / pharmacokinetics. Animals. Disease Models, Animal. Electromagnetic Fields. Hepatic Artery. Magnetics. Male. Neoplasm Transplantation. Particle Size. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313670.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 0 / Antimetabolites, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


51. Silva SL, Silva SF, Cavalcante RO, Mota RS, Carvalho RA, Moraes MO, Campos HH, Moraes ME: Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc; 2004 May;36(4):1004-6
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine.
  • PURPOSE: To investigate the effect of mycophenolate mofetil on Walker's carcinosarcoma, without versus with the growth and regression of cyclosporine.
  • CONCLUSIONS: MMF produces an anti-tumoral effect against Walker's carcinosarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use
  • [MeSH-minor] Animals. Cell Division / drug effects. Cyclosporine / therapeutic use. Male. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15194349.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


52. Kurth AA, Kim SZ, Bauss F, Müller R, Hovy L: [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis]. Z Orthop Ihre Grenzgeb; 2000 Mar-Apr;138(2):146-51
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis].
  • [Transliterated title] Eine antiosteolytische Therapie bewahrt die Trabekelstruktur und die mechanischen Eigenschaften des Knochens in Tumorosteolysen.
  • PURPOSE OF THE STUDY: Little is known about the effect of a tumor on the trabecular architecture, therefore we employed an animal model for the assessment of bone quality in tumor osteolysis to determine the alterations of the trabecular architecture in tumor osteolysis and after an interventional treatment with a bisphosphonate.
  • METHODS: To assess the bone mass and the micro-architecture of the trabecular bone in tumor osteolysis we employed a micro-computed tomography system.
  • An interventional treatment of the animals with a bisphosphonate increased the bone mineral content, mechanical and architectural parameters compared to the non-treated, tumor-bearing animals.
  • CONCLUSIONS: These results clearly show a beneficial effect of an anti-osteolytic treatment with a bisphosphonate in regard of bone quality in tumor-induced osteolysis.
  • [MeSH-major] Bone Neoplasms / pathology. Bone and Bones / drug effects. Diphosphonates / pharmacology. Osteolysis / pathology
  • [MeSH-minor] Animals. Bone Density / drug effects. Bone Resorption / pathology. Carcinoma 256, Walker / pathology. Disease Models, Animal. Humans. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820881.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


53. Liu X, Heng WS, Paul, Li Q, Chan LW: Novel polymeric microspheres containing norcantharidin for chemoembolization. J Control Release; 2006 Nov;116(1):35-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemoembolization has been found to be a potentially effective method of treating certain types of cancer.
  • Norcantharidin, which possesses anti-tumor properties, was used to investigate the application of drug-containing microspheres for chemoembolization.
  • The growth inhibitory effect was concentration and time dependent.
  • These microspheres also exhibited excellent embolization and therapeutic effects on rats with transplanted tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Bicyclo Compounds, Heterocyclic / administration & dosage. Bicyclo Compounds, Heterocyclic / pharmacology. Chemoembolization, Therapeutic
  • [MeSH-minor] Alginates. Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Cell Line, Tumor. Drug Delivery Systems. Humans. Kinetics. Lactic Acid. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / pathology. Male. Microscopy, Electron, Scanning. Microspheres. Neoplasm Transplantation. Particle Size. Polyglycolic Acid. Polymers. Rats. Rats, Sprague-Dawley. Solubility. Survival

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050026.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Alginates; 0 / Antineoplastic Agents; 0 / Bicyclo Compounds, Heterocyclic; 0 / Polymers; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; 5442-12-6 / norcantharidin
  •  go-up   go-down


54. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K: Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res; 2000 Jun 1;60(11):2988-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To improve their pharmacological profiles, a new macromolecular prodrug, denoted T-0128, was synthesized.
  • This prodrug is a novel CPT analogue (T-2513)-carboxymethyl (CM) dextran conjugate via a triglycine spacer, with a molecular weight of Mr 130,000.
  • This study was designed to test the concept that the rational design of a CPT-polymer conjugate would increase the efficacy of the parent drug.
  • The in vivo antitumor study against Walker-256 carcinoma demonstrated that T-0128 was 10 times as active as T-2513, supporting this concept.
  • Even a single i.v. injection of T-0128 at 6 mg/kg (based on the amount of T-2513 bound to CM dextran) induced complete regression of MX-1 mammary carcinoma.
  • T-0128 at 10 mg/kg weekly for 3 weeks (one-tenth of its MTD) cured LX-1 lung carcinoma.
  • These demonstrate the broad range of therapeutic doses achieved with T-0128.
  • Pharmacokinetic studies were performed to correlate the efficacy results obtained for T-0128 with plasma and tissue drug concentrations using Walker-256 tumor-bearing rats.
  • The significant increases in the amount and exposure time of released T-2513 in the tumor explain well the enhanced efficacy of T-0128.
  • [MeSH-major] Breast Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dextrans / pharmacology. Lung Neoplasms / drug therapy. Prodrugs / pharmacology. Topotecan / analogs & derivatives
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Chromatography, Gel. Chromatography, High Pressure Liquid. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Female. HeLa Cells. Humans. Male. Mice. Mice, Nude. Neoplasm Transplantation. Rats. Rats, Wistar. Time Factors. Tissue Distribution. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10850447.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Prodrugs; 0 / T 0128; 0 / T 2153; 7M7YKX2N15 / Topotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; K3R6ZDH4DU / Dextrans; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Wyld L, Reed MW, Brown NJ: Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer; 2001 May 18;84(10):1384-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cell death response to photodynamic therapy is dependent on dose and cell type.
  • PDT-induced cell death, by either apoptosis or necrosis may vary with cell type or PDT dose.
  • 5 cell types were treated with varying doses of aminolaevulinic acid-induced PDT and the type of cell death analysed.
  • The mode of cell death was found to depend on both cell type and light dose.
  • [MeSH-major] Cell Death / drug effects. Endothelium, Vascular / cytology. Photochemotherapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Breast Neoplasms. Carcinoma 256, Walker. Cells, Cultured. Dose-Response Relationship, Drug. Female. Genes, p53. Humans. Rats. Tumor Cells, Cultured. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Oncol Res. 1994;6(12):569-79 [7787250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5241-6 [8643560.001]
  • [Cites] Cytometry. 1997 May 1;28(1):11-24 [9136751.001]
  • [Cites] Int J Cancer. 1998 Apr 13;76(2):259-66 [9537589.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):823-30 [8167895.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 10;1366(1-2):151-65 [9714783.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):72-81 [10408696.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9357-60 [9545256.001]
  • (PMID = 11355951.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2363631
  •  go-up   go-down


56. Harano N, Ono K, Hidaka K, Kai A, Nakanishi O, Inenaga K: Differences between orofacial inflammation and cancer pain. J Dent Res; 2010 Jun;89(6):615-20
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this question, we compared the effects of an anti-inflammatory drug, indomethacin, on pain and neurochemical changes in the medullary dorsal horn in orofacial inflammation and cancer models.
  • The same procedure suppressed allodynia and hyperalgesia in the cancer model, but the suppression was weak when compared with that in the inflammation model.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Facial Neoplasms / physiopathology. Facial Pain / physiopathology. Indomethacin / therapeutic use
  • [MeSH-minor] Animals. Calcitonin Gene-Related Peptide / analysis. Calcitonin Gene-Related Peptide / drug effects. Carcinoma 256, Walker / physiopathology. Disease Models, Animal. Galanin / analysis. Galanin / drug effects. Hot Temperature. Hyperalgesia / drug therapy. Hyperalgesia / physiopathology. Inflammation / physiopathology. Injections, Intraperitoneal. Male. Neuropeptides / analysis. Neuropeptides / drug effects. Neurotransmitter Agents / analysis. Pain Threshold / drug effects. Pain Threshold / physiology. Physical Stimulation. Rats. Rats, Wistar. Reaction Time / drug effects. Reaction Time / physiology. Substance P / analysis. Substance P / drug effects. Touch. Trigeminal Caudal Nucleus / drug effects. Trigeminal Caudal Nucleus / physiopathology. Vibrissae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332329.001).
  • [ISSN] 1544-0591
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Neuropeptides; 0 / Neurotransmitter Agents; 33507-63-0 / Substance P; 83652-28-2 / Calcitonin Gene-Related Peptide; 88813-36-9 / Galanin; XXE1CET956 / Indomethacin
  •  go-up   go-down


57. Chen JH, Wang L, Ling R, Li Y, Wang Z, Yao Q, Ma Z: Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig Dis Sci; 2004 Aug;49(7-8):1170-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty Walker-256 hepatoma-bearing rats were divided into two groups at random, with 15 rats in each.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / metabolism. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / administration & dosage. Doxorubicin / metabolism. Liver Neoplasms, Experimental / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pharm Res. 2002 Jun;25(3):229-39 [12135091.001]
  • [Cites] Int J Cancer. 1983 Jul 15;32(1):7-12 [6683250.001]
  • [Cites] J Pharm Sci. 2003 Jan;92(1):161-72 [12486692.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1989-91 [15222053.001]
  • [Cites] Kongressbd Dtsch Ges Chir Kongr. 2002;119:821-8 [12704931.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(2):122-6 [2189589.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4584-7 [3396009.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1835-41 [2894892.001]
  • [Cites] Sel Cancer Ther. 1990 Fall;6(3):119-27 [2281201.001]
  • [Cites] Drug Des Deliv. 1989 Jun;4(4):295-302 [2775449.001]
  • (PMID = 15387341.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


58. Yu S, Peng HD, Ju DW, Wei PK, Xu L, Lao LX, Li J: Mechanisms of treatment of cancer pain with a topical Chinese herbal formula in rats. Chin Med J (Engl); 2009 Sep 5;122(17):2027-31
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of treatment of cancer pain with a topical Chinese herbal formula in rats.
  • BACKGROUND: Pain has a substantial impact on patients' activities and overall quality of life, but current conventional drugs have debilitating side effects, including gastrointestinal disorders.
  • Thus there is a pressing need for new therapies with fewer side effects to alleviate cancer pain.
  • We recently developed a topical herbal formula Xiaotan Tongluo analgesic gel (XTTL gel) based on the principles of traditional Chinese herbalism, and we have received positive feedback from bone cancer pain patients.
  • METHODS: The rat model of bone cancer pain was established by inoculating Walker-256 rat carcinoma cells directly into the right tibial medullary cavity of Wistar rats.
  • (1) sham bone cancer control (sham group): vehicle (PBS) inoculation without carcinoma cells plus topical administration of blank gel;.
  • (2) Sham treatment control (vehicle group): Walker-256 cell inoculation plus topical administration of blank gel;.
  • (3) XTTL gel treatment (treatment group): Walker-256 cell inoculation plus topical administration of XTTL gel.
  • XTTL gel treatments were applied daily for 7 days starting on day 14 following inoculation.
  • Outcomes were assessed 21 days after inoculation by mechanical allodynia, histological staining, and by measuring concentrations of type I collagen carboxy-terminal telopeptide (ICTP) and bone-specific alkaline phosphatase (BAP) in serum.
  • RESULTS: Fourteen days after cancer cell incubation, significant mechanical allodynia in the ipsilateral hind paw and tumor growth in proximal end of the tibia were observed in the vehicle and treatment groups but not in the sham group.
  • At day 21, mechanical withdrawal thresholds in treatment group rats were significantly higher ((4.8557 +/- 0.8336) g) compared with those of the vehicle group ((1.8630 +/- 1.4369) g, P < 0.05).
  • [MeSH-major] Bone Neoplasms / complications. Drugs, Chinese Herbal / therapeutic use. Pain / drug therapy. Pain / etiology
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Animals. Body Weight. Cell Line, Tumor. Collagen Type I. Female. Peptide Fragments / blood. Peptides. Procollagen / blood. Random Allocation. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781391.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Drugs, Chinese Herbal; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


59. Gade TP, Koutcher JA, Spees WM, Beattie BJ, Ponomarev V, Doubrovin M, Buchanan IM, Beresten T, Zakian KL, Le HC, Tong WP, Mayer-Kuckuk P, Blasberg RG, Gelovani JG: Imaging transgene activity in vivo. Cancer Res; 2008 Apr 15;68(8):2878-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The successful translation of gene therapy for clinical application will require the assessment of transgene activity as a measure of the biological function of a therapeutic transgene.
  • Although current imaging permits the noninvasive detection of transgene expression, the critical need for quantitative imaging of the action of the expressed transgene has not been met.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2180-9 [10561274.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3738-47 [17575240.001]
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):321-5 [10700150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5151-5 [10805778.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):315-20 [10935486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12278-82 [11050247.001]
  • [Cites] MAGMA. 2001 May;12(2-3):141-52 [11390270.001]
  • [Cites] NMR Biomed. 2001 Jun;14(4):278-83 [11410946.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5 [11481488.001]
  • [Cites] Circulation. 2002 Jul 30;106(5):631-6 [12147548.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Drug Discov Today. 2003 Nov 1;8(21):990-6 [14643162.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):616-20 [15004806.001]
  • [Cites] Magn Reson Med. 2004 Jul;52(1):169-73 [15236381.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jun;79(11):3523-6 [6954498.001]
  • [Cites] Biochim Biophys Acta. 1986 Apr 11;881(2):268-75 [3513846.001]
  • [Cites] Magn Reson Med. 1988 Jul;7(3):319-36 [3205148.001]
  • [Cites] Clin Chem. 1989 Mar;35(3):392-5 [2920404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):492-6 [2296605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(8):3112-6 [2326269.001]
  • [Cites] Magn Reson Med. 1991 May;19(1):113-23 [2046526.001]
  • [Cites] Magn Reson Imaging. 1991;9(4):621-5 [1664017.001]
  • [Cites] Magn Reson Imaging. 1992;10(3):471-85 [1406098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6733-7 [7624312.001]
  • [Cites] Radiology. 1996 Mar;198(3):795-805 [8628874.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4087-95 [8797571.001]
  • [Cites] NMR Biomed. 1996 Jun;9(4):141-55 [9015801.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1115-9 [9415319.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] Breast Cancer Res Treat. 1997 Nov-Dec;46(2-3):303-12 [9478282.001]
  • [Cites] Nat Med. 1998 Jun;4(6):655-7 [9623964.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4075-8 [9751613.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):339-45 [9816177.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):375-8 [10207887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9821-6 [10449778.001]
  • [Cites] Nat Med. 2000 Mar;6(3):351-5 [10700241.001]
  • (PMID = 18413756.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA086438; United States / NCI NIH HHS / CA / R24 CA083084-03; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA083084-03; United States / NCI NIH HHS / CA / CA086438-07; United States / NCI NIH HHS / CA / P50 CA086438-07; United States / NCI NIH HHS / CA / P50CA86438; United States / NCI NIH HHS / CA / R24CA83084; United States / NCI NIH HHS / CA / R24 CA083084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 284SYP0193 / Fluorine
  • [Other-IDs] NLM/ NIHMS49923; NLM/ PMC3043616
  •  go-up   go-down


60. Liu H, Baliga R: Effect of iron chelator, hydroxyl radical scavenger and cytochrome P450 inhibitors on the cytotoxicity of cisplatin to tumor cells. Anticancer Res; 2000 Nov-Dec;20(6B):4547-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: This study was designed to determine whether these agents affect the tumoricidal efficacy of CP to LLC-WRC 256 tumor cells.
  • RESULTS: CP was cytotoxic to the tumor cells in a dose and time dependent manner.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma 256, Walker / drug therapy. Cisplatin / pharmacology. Cytochrome P-450 Enzyme Inhibitors. Enzyme Inhibitors / pharmacology. Free Radical Scavengers / pharmacology. Iron Chelating Agents / pharmacology
  • [MeSH-minor] Animals. Cell Death. Cimetidine / pharmacology. Deferoxamine / pharmacology. Dimethyl Sulfoxide / pharmacology. Dose-Response Relationship, Drug. Drug Interactions. Piperonyl Butoxide / pharmacology. Rats. Time Factors

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Piperonyl butoxide .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205302.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytochrome P-450 Enzyme Inhibitors; 0 / Enzyme Inhibitors; 0 / Free Radical Scavengers; 0 / Iron Chelating Agents; 80061L1WGD / Cimetidine; J06Y7MXW4D / Deferoxamine; LWK91TU9AH / Piperonyl Butoxide; Q20Q21Q62J / Cisplatin; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down






Advertisement